A new secondary treatment containing Omega 3 has been approved for patients at risk of myocardial infarction, by the Therapeutic Goods Administration (TGA).
Containing a combination of Omega 3 and Ethyl Esters 90, Omacor has been licensed for use as an adjuvant treatment for the secondary prevention of myocardial infarction in addition to another standard therapy.
A spokesperson for manufacturer Abbott said Omacor is different to over-the-counter Omega 3 preparations as it contains higher concentrations of beneficial ingredients (84 per cent EPA/DHA) and Ethyl Esters rather than Marine Triglycerides.
“Omacor is the only product of its kind, which has been tested and proven in large randomise morbidity and mortality placebo controlled trials.
“A study of post myocardial infarction patients found that Omacor demonstrated a statistically significant improvement in morbidity and mortality when combined with standard therapy,” the spokesperson said.
A four-way analysis of the drug showed decrease in the relative risk of death by 20 per cent and cardiovascular death by 30 per cent compared with placebo.
The spokesperson added that patients the benefits of the drug could be seen within three months, with patients who had been given Omacor having a significantly lower risk of mortality than those on a placebo.